JOURNEY

📅 Upcoming

🕒 Recent(90d)

News

• BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
  BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
  fiercebiotech · 19h ago
• Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
  With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
  biospace · 4d ago
• Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera
  AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.
  fiercebiotech · 5d ago
• Eli Lilly tops new biopharma ranking on launch success, development speed
  Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 large, global bioph…
  fiercebiotech · 6d ago
• STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
  An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal to make them more available
  stat · 7d ago
• [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services
  This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.
  biopharma_dive · 7d ago
• FDA has recommitted to adcomms—but to what end?
  The FDA will hold advisory committee meetings this week for previously rejected investigational therapies from Replimune and Capricor Therapeutics. Some industry leaders were surprised the meetings…
  biospace · 8d ago
• Scribe secures $129M in a rare gene editing IPO
  The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.
  biopharma_dive · 11d ago
• STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
  A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question — whether it reduces cardiovascular risk
  stat · 11d ago
• From Big Pharma to specialty: why moving closer to the patient changes everything
  Working at a Big Pharma has its benefits, but there are limitations too. SERB Pharmaceuticals’ Thomas Kolaras discusses how moving to a midsize company creates new opportunities for sharpened think…
  biospace · 12d ago